B
Bicara Therapeutics Inc. (BCAX)
NGM – Real vaqt narxi. Valyuta: USD
22.38
-0.54 (-2.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
22.38
-0.54 (-2.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Bicara Therapeutics Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, qattiq o'smalar uchun ikki funksiyali terapiyani ishlab chiqish bilan shug'ullanadi. Uning yetakchi dasturi ficerafusp alfa bo'lib, bu ikki funksiyali antiteladir, u qattiq o'smalarni davolash uchun klinik tasdiqlangan epidermal o'sish omilining retseptoriga yo'naltirilgan monoklonal antitelani inson transformatsiyalovchi o'sish omili betasi bilan birlashtiradi. Kompaniya 2018-yilda tashkil etilgan va Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |
| Mr. Ivan Hyep M.B.A. | CFO & Treasurer |
| Mr. Jean-Paul Rodrique | Senior VP & Global Head of Quality Assurance |
| Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director |
| Ms. Angela Windt | VP & Head of Regulatory Affairs |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary |
| Ms. Pauline Dufresne | Chief People Officer |
| Ms. Rachel Salazar | SVP of R&D Strategy and Operations |
| Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | bcax-20260511.htm |
| 2026-04-27 | DEFA14A | defa14anotice2026.htm |
| 2026-04-27 | DEF 14A | bcax-20260427.htm |
| 2026-03-31 | S-8 | bicara-sx8evergreeninducem.htm |
| 2026-03-30 | 8-K | bcax-20260330.htm |
| 2026-03-30 | 10-K | bcax-20251231.htm |
| 2026-02-26 | 8-K | d938194d8k.htm |
| 2026-02-19 | 8-K | bcax-20260219.htm |
| 2026-01-12 | 8-K | bcax-20260112.htm |
| 2025-12-08 | 8-K | bcax-20251206.htm |